Epigenetic Therapeutics: Global Markets

Jul 2023| PHM272A| BCC Publishing
Sample Report

Report Highlights

The global market for epigenetic therapeutics is estimated to increase from $6.8 billion in 2023 to reach $9.8 billion by 2028, at a compound annual growth rate (CAGR) of 7.7% from 2023 through 2028.

Report Includes

  • 77 tables
  • A comprehensive overview of the global markets for epigenetic therapeutics
  • Analyses of the global market trends with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Understanding of the upcoming market potential for epigenetic therapeutics with an emphasis on new products and technologies, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size and revenue forecast for the global epigenetic therapeutics market, and corresponding market share analysis product type and region
  • In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in epigenomics, and COVID-19 impact on the industry
  • Coverage of the technological, economic, and business considerations of the market for epigenetic therapeutics, with analyses and growth forecasts through 2028
  • A look at the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights on epigenetic therapeutics
  • Review of patent trends and research publications for innovations in the genome-editing technologies
  • Insight into the recent industry structure, government regulations and policies, development issues, and the vendor landscape
  • Analysis of the competitive environment and market opportunities based on the company’s business strategies, product mapping, and operational integration
  • Descriptive company profiles of the leading pharma corporations, including AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte

Report Scope

This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

This report, however, does not cover epigenetic diagnostic assays and instruments.

Frequently Asked Questions (FAQs)

The global epigenetic therapeutics market is projected to grow from $6.4 billion in 2022 to $9.8 billion in 2028, at a compound annual growth rate (CAGR) of 7.7% during the forecast period.
The epigenetic therapeutics market is majorly driven by the rising chronic disease such as cancer, diabetes, cardiovascular diseases and neurological diseases and increasing adaption of epigenetic therapeutic treatment to prevent the disease progression. Increasingly popularity in the field of drug discovery is additional factor propelling the growth of this market.
The global epigenetic therapeutics market is segmented based on the product type such PARP inhibitors, Kinase inhibitors, HDAC inhibitors, DNMT inhibitors, KMT inhibitors, and by geographic region.
PARP inhibitors will dominate the market by the end of 2028.
Key companies in the market includes AstraZeneca, Incyte, GSK Plc, Seagen Inc, Bristol-Myers Squibb (Celegene), Clovis Oncology and Epizyme Inc.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $6.4 billion
Market size forecast $9.8 billion
Growth rate CAGR of 7.7% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered product type and region
Regions covered North America, Latin America, Europe, Asia-Pacific, and Rest of the World
Countries covered U.S., Canada, Mexico, Brazil, Argentina, Chile, Germany, U.K., France, Italy, Spain, China, Japan, India, Middle East, and Africa
Key Market Drivers
  • Aging Population
  • Risk of Cancer in Major Countries
  • Penetration of Targeted Medicine in Emerging Markets
Companies studied

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
. Title/Chapter NamePagesPrice Member Price
Full Report: Epigenetic Therapeutics: Global Markets155 $5,500 Free
Chapter- 1: Introduction6Free DownloadFree
Chapter- 2: Summary and Highlights3$250Free
Chapter- 3: Market Overview and Definitions6$214Free
Chapter- 4: Market Trends13$464Free
Chapter- 5: Market Breakdown by Product Type11$393Free
Chapter- 6: Impact of COVID-193$107Free
Chapter- 7: Market Breakdown by Region8$286Free
Chapter- 8: Emerging/Upcoming Technologies2$71Free
Chapter- 9: Competitive Landscape5$179Free
Chapter- 10: Patent Analysis12$429Free
Chapter- 11: Pipeline Analysis65$2,321Free
Chapter- 12: Company Profiles20$714Free
Chapter- 13: Appendix: Acronyms1$36Free
Epigenetic Therapeutics: Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.